Previous 10 | Next 10 |
home / stock / rhhby / rhhby articles
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) said the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic ta...
Monday, Roche Holdings AG (OTC:RHHBY) announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal ...
Wedbush initiated coverage on Monte Rosa Therapeutics Inc (NASDAQ:GLUE), a company focused on developing molecular glue degraders (M...
Tuesday, Repare Therapeutics Inc (NASDAQ:RPTX) announced to regain global development and commercialization rights to camonsertib (RP-350...
HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 progra...
Friday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for F...
In a recent revelation, CNBC’s Mad Money host Jim Cramer disclosed that the financial market values artificial intelligence (AI) technology m...
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...